Use this button to switch between dark and light mode.

Share your feedback on this Case Opinion Preview

Thank You For Submiting Feedback!

Experience a New Era in Legal Research with Free Access to Lexis+

  • Case Opinion

In re Ephedra Prods. Liab. Litig.

In re Ephedra Prods. Liab. Litig.

United States District Court for the Southern District of New York

September 19, 2005, Decided ; September 20, 2005, Filed

04 MD 1598 (JSR)

Opinion

 [*184] OPINION AND ORDER

PERTAINS TO ALL CASES

JED S. RAKOFF, U.S.D.J.

In Case Management Order No. 14 dated June 23, 2005, the Court granted in part and denied in part the respective motions of the Defendants' Coordinating Counsel (the "DCC") and Plaintiffs' Coordinating Counsel (the "PCC") to exclude, pursuant to Rule 702, Fed. R. Evid., and Daubert v. Merrell Dow Pharms., 509 U.S. 579, 125 L. Ed. 2d 469, 113 S. Ct. 2786 (1993), the testimony of certain "generic" experts. Specifically, the Court held that

the PCC's experts shall not be permitted to testify with "medical certainty" or "scientific certainty" that ephedra caused the alleged injuries. However, they will be permitted to testify (if otherwise admissible under applicable state and federal law) that ephedra may be a contributing cause of stroke, cardiac injury, and seizure in some people. A Memorandum Order [or, as here, an Opinion and Order] further detailing and elaborating on these ruling and including other holdings, such as more particularized rulings on the opinions offered by Dr. James Knochel and Dr. Kristie L. Ebi,  [**2]  will be filed in due course.

Case Management Order No. 14, June 23, 2005, P 3. As promised, this Opinion and Order serves to explain, elaborate, and refine those determinations and decide certain related, outstanding issues.

By way of background, there are presently consolidated before the Court about 500 civil actions claiming personal injury or wrongful death caused by dietary supplements containing ephedra. Some 360 were transferred here pursuant to 28 U.S.C. § 1407 for pretrial purposes only, while the remainder -- cases against the former Twin Laboratories Inc., a debtor in bankruptcy in this district, plus a few other cases commenced in this district -- are here for all purposes. Following consolidation,  [*185]  the Court issued Case Management Order No. 1, dated April 26, 2004, which among other things, provided that the PCC

shall identify, in a document served on all parties, generic expert witnesses who are reasonably expected to testify [at subsequent trials] for the plaintiffs on issues of general or widespread applicability ("Generic Experts"), including, but not limited to, experts who will testify on general causation. The plaintiffs [**3]  may identify up to three Generic Experts with respect to each of the following categories of injuries: (a) ischemic stroke, (b) hemorrhagic stroke, (c) seizures, (d) cardiac injury, (e) psychotic injury, and (f) primary pulmonary hypertension. For each Generic Expert so identified, Plaintiffs' Coordinating Counsel, on behalf of all plaintiffs, shall serve upon all parties the disclosures required by Fed. R. Civ. P. 26(a)(2), except that such disclosures need not include such testimony, if any, that such Generic Expert is expected to offer relating only to liability or damages as to a particular plaintiff.

Read The Full CaseNot a Lexis Advance subscriber? Try it out for free.

Full case includes Shepard's, Headnotes, Legal Analytics from Lex Machina, and more.

393 F. Supp. 2d 181 *; 2005 U.S. Dist. LEXIS 20259 **; 2005 WL 8178810

In re: EPHEDRA PRODUCTS LIABILITY LITIGATION

Subsequent History: As Amended, September 25, 2005.

Later proceeding at Winters v. Gen. Nutrition Corp. (In re Ephedra Prods. Liab. Litig.), 2005 U.S. Dist. LEXIS 22418 (S.D.N.Y., Oct. 2, 2005)

Prior History: In re Ephedra Prods. Liab. Litig., 231 F.R.D. 167, 2005 U.S. Dist. LEXIS 19586 (S.D.N.Y., Sept. 11, 2005)

CORE TERMS

ephedra, scientific, stroke, ephedrine, studies, generic, products, causation, reliable, cases, seizures, alkaloids, blood pressure, causality, cardiac, causes, statistically significant, hemorrhagic, patients, interval, effects, epidemiological, scientists, injuries, dietary supplement, enrolled, dose, heat, increases, ban

Evidence, Admissibility, Expert Witnesses, Types of Evidence, Testimony, General Overview, Expert Witnesses, Scientific Evidence, Business & Corporate Compliance, Governments, Agriculture & Food, Federal Food, Drug & Cosmetic Act, Environmental Law, Hazardous Wastes & Toxic Substances, Toxic Torts, Torts, Elements, Causation, Causation in Fact, Proximate Cause, Daubert Standard, Standards for Admissibility